Directorate change
Appointment of Ian Clark as Non-Executive Director
January 3, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) ("Shire"' / the "Company")
announces the appointment of Ian Clark as a Non-Executive Director of the
Company with effect from the date of this announcement.
Mr. Clark served as Chief Executive Officer and Director of Genentech Inc (part
of the Roche Group) and Head of North American Commercial Operations for Roche
until December 31, 2016, having held several senior strategy, operations and
commercially focused roles since joining Genentech in 2003. Prior to this Mr.
Clark held various senior operational, sales and marketing roles in other
pharmaceutical and healthcare companies. He is currently appointed as a
Non-Executive Director of TerraVia Holdings Inc. where he serves as Chairman of
the Compensation Committee and as a member of the Nominating and Corporate
Governance Committee.
Susan Kilsby, Shire's Chairman, commented: "We are very pleased to announce
Ian's appointment at this important time; his in-depth knowledge of the
biotechnology sector and breadth of operational experience stand to serve Shire
well as we look forward to growing our business and addressing unmet patient
needs world-wide."
Mr. Clark added: "Shire has demonstrated commitment to being the global leader
in rare diseases and to delivering value to its patients, physicians,
shareholders and other stakeholders. I look forward to working with Susan and
the rest of the Board in pursuing a successful future for the Company."
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
Investor Relations
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874
Media
Lisa Adler lisa.adler@shire.com +1 617 588 8607
Debbi Ford debbi.ford@shire.com +1 617 949 9083
NOTES TO EDITORS
No further information is required to be disclosed pursuant to 9.6.13R of the
UK Listing Rules.
About Shire
Shire is the leading global biotechnology company focused on serving people
with rare diseases and other highly specialized conditions. We strive to
develop best-in-class products, many of which are available in more than 100
countries, across core therapeutic areas including Hematology, Immunology,
Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal /
Internal Medicine / Endocrine and Hereditary Angioedema; and a growing
franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and
deliver breakthrough therapies for the hundreds of millions of people in the
world affected by rare diseases and other high-need conditions, and who lack
effective therapies to live their lives to the fullest.
www.shire.com